Low Incidence of Acute Rejection after Living-Donor Liver Transplantation: Immunologic Analyses by Mixed Lymphocyte Reaction using a Carboxyfluorescein Diacetate Succinimidyl Ester Labeling Technique

Tanaka, Yuka; Ohdan, Hideki; Onoe, Takashi; Mitsuta, Hiroshi; Tashiro, Hirotaka; Itamoto, Toshiyuki; Asahara, Toshimasa

doi:10.1097/01.tp.0000161667.99145.20

Cited by 63 publications

(58 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…T-cell proliferation was visualized by twofold serial dilutions of the fluorescence intensity of CFSE. CD4 + and CD8 + T-cell proliferation and stimulation index (SI) were quantified using a previously described method [15,16].…”

Section: Immune Monitoring By In Vitro Mlr Assaysmentioning

confidence: 99%

Different sensitivity of rituximab-treatment to B-cells between ABO-incompatible kidney and liver transplantation

et al. 2016

Self Cite

View full text Add to dashboard Cite

A desensitization protocol with rituximab is currently widely used for kidney transplantation (KT) and liver transplantation (LT) across the ABO blood group-incompatible (ABO-I) barrier. However, it remains to be elucidated whether rituximab is equally effective for B-cell and T-cell immune responses in both KT and LT recipients. To clarify these effects of rituximab, we enrolled 46 KT and 77 LT recipients in this study. The proportion of peripheral blood B-cells was determined at the perioperative period. T-cell responses to allostimulation were evaluated by a mixed lymphocyte reaction (MLR) assay. One week after rituximab administration, peripheral B-cells became undetectable in ABO-I KT recipients but remained detectable in some of the ABO-I LT recipients; B-cells were undetectable in both groups by week 2. B-cells remained below the detection limit throughout the first year in the ABO-I KT recipients, whereas they reappeared in the periphery after 6months in the ABO-I LT recipients. There were no significant differences in alloreactive T-cell responses based on MLR analyses between ABO-I and ABO-compatible groups. This study indicates that rituximab has differing B-cell sensitivity between KT and LT recipients and a minimal effect on the alloreactive T-cell responses in KT and LT recipients.

show abstract

Section: Immune Monitoring By In Vitro Mlr Assaysmentioning

confidence: 99%

Different sensitivity of rituximab-treatment to B-cells between ABO-incompatible kidney and liver transplantation

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Methyl prednisolone (1 g/day) was intravenously administered for 3 consecutive days (one or two courses) to treat histologically proven or mixed lymphocytic reactionproven acute cellular rejection (37).…”

Section: Immunosuppressionmentioning

confidence: 99%

Safety and Feasibility of Diet-Treated Donors With Steatotic Livers at the Initial Consultation for Living-Donor Liver Transplantation

Oshita

Tashiro²,

Amano³

et al. 2012

Transplantation

Self Cite

View full text Add to dashboard Cite

show abstract

“…CFSE labeling to assess alloantigen responses has been used widely in murine systems (52). CFSE-MLR assay was used recently in a single human study of living-donor liver transplant recipients to distinguish rejection on suspicious biopsies (53). Despite the theoretic appeal of this assay, to date, no human studies have demonstrated a correlation between donor antigen-induced proliferation and the ability to wean immunosuppression or the development of tolerance.…”

Section: Measurement Of Cell Proliferation By Cfse Labelingmentioning

confidence: 99%

How Can We Measure Immunologic Tolerance in Humans?

Najafian

Albin²,

Newell³

2006

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Prevention and treatment of allograft rejection in organ transplant recipients relies primarily on non-antigen-specific immunosuppression, with all its associated potential hazards and costs. Currently, the status of the recipient immune response is measured by monitoring pharmacologic drug levels and clinical/pathologic evaluation of graft function. Development of reliable assays that can measure accurately the status of the immune response not only would help clinicians customize the prescription of immunosuppressive drugs in individual patients but also may allow their complete withdrawal in some patients with immunologic tolerance. Furthermore, these assays would facilitate the safe evaluation of novel tolerogenic regimens. Achieving this goal has proved to be very difficult because it requires both a more in-depth understanding of complex mechanisms of tolerance and also identification of transplant patients with acquired tolerance to an allograft that can be studied. This review discusses the current understanding of tolerance mechanisms and outlines the unique and specific challenges in development of tolerance/monitoring assays in the field of transplantation. In addition, several of the most promising candidate assays are discussed in detail.

show abstract

Low Incidence of Acute Rejection after Living-Donor Liver Transplantation: Immunologic Analyses by Mixed Lymphocyte Reaction using a Carboxyfluorescein Diacetate Succinimidyl Ester Labeling Technique

Abstract: The results of CFSE-MLR assays, which could be used for rigorously monitoring rejection, provided evidence of low incidence of acute rejection after LDLT.

Cited by 63 publications

References 24 publications

Different sensitivity of rituximab-treatment to B-cells between ABO-incompatible kidney and liver transplantation

Different sensitivity of rituximab-treatment to B-cells between ABO-incompatible kidney and liver transplantation

Safety and Feasibility of Diet-Treated Donors With Steatotic Livers at the Initial Consultation for Living-Donor Liver Transplantation

How Can We Measure Immunologic Tolerance in Humans?

Contact Info

Product

Resources

About